ADMA Biologics Inc ADMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADMA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $13.08
- Day Range
- $12.94–13.35
- 52-Week Range
- $3.06–14.03
- Bid/Ask
- $13.12 / $13.20
- Market Cap
- $3.05 Bil
- Volume/Avg
- 2.8 Mil / 3.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 120.11
- Price/Sales
- 10.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 624
- Website
- https://www.admabiologics.com
Comparables
Valuation
|
Metric
|
ADMA
|
ICVX
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | 120.11 | — | — |
Price/Book Value | 19.84 | 3.30 | 8.11 |
Price/Sales | 10.58 | — | — |
Price/Cash Flow | 68.98 | — | — |
Price/Earnings
ADMA
ICVX
DYN
Financial Strength
|
Metric
|
ADMA
|
ICVX
|
DYN
|
|---|---|---|---|
Quick Ratio | 1.79 | 17.59 | 20.28 |
Current Ratio | 5.21 | 18.06 | 21.83 |
Interest Coverage | 0.78 | — | — |
Quick Ratio
ADMA
ICVX
DYN
Profitability
|
Metric
|
ADMA
|
ICVX
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | 6.68% | −29.30% | −77.53% |
Return on Equity (Normalized) | 15.61% | −31.87% | −94.92% |
Return on Invested Capital (Normalized) | 13.33% | −34.69% | −88.19% |
Return on Assets
ADMA
ICVX
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Lybwsbhybv | Sslzn | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fmdpvwxdv | Cxsgwq | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lzqlzftt | Ftxbx | $118.7 Bil | |||
| Moderna Inc
MRNA
| Fsvdbrmh | Mxng | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zygzwhfk | Qjndy | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Vrhgvyj | Kdzm | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Wflspgkn | Tqzs | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lxdtzszr | Rvzkwwt | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Znmvyxwr | Vsjp | $15.0 Bil | |||
| Incyte Corp
INCY
| Gbdtkpn | Htpkgp | $13.5 Bil |